K-001 Treatment of Advanced Pancreatic Cancer: Clinical Trial of Monotherapy's Tolerability

K-001 Treatment of Advanced Pancreatic Cancer: Phase I Clinical Trial of Monotherapy's Tolerability

This study is an open and single-center Phase I clinical research on patients with advanced pancreatic cancer, for evaluating their adverse reactions or tolerance to K-001, so as to determine the safe and reasonable dosage and dosing regimen.

Study Overview

• Status: Completed
• Conditions: Pancreatic Cancer
• Intervention / Treatment: Drug: K-001

Detailed Description

According to past experience to toxicology studies and clinical test, K-001 at a dose of 2700mg/day has a good safety profile for human body. Upon observation, pancreatic cancer patients receiving a medication at 2160mg/day (1080mg BID) have had good therapeutic efficacy, no sign of significant toxicity.

Dosing regimen:

Phase I clinical test: maximum dose of monotherapy at 2700mg/day. Four groups of repeated administration of monotherapy, at least 3 patients for each group.

Group A: 2700mg/d (1350mg BID); Group B: 3240mg/d (1620mg BID); Group C: 3780mg/d (1890mg BID); Group D: 4320mg/d (2160mg BID). Twice a day, to be taken with warm water on an empty stomach; 4 weeks' administration for each group.

In case of severe adverse reactions associated with the test drug, or if half of the participants show adverse reactions at Ⅲ level and above, the test should be terminated. The maximum dosage not causing the above-described situation shall be considered as the maximum tolerated dose or the biologically effective dose. After the test, continuous medication shall be given upon request from patients.

• Study Type: Interventional
• Enrollment (Actual): 12
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Shanghai
    • Shanghai, Shanghai, China, 200080
      • Shanghai General Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

Disease-related criteria for inclusion:

1. Based on histodiagnosis or cytodiagnosis;
2. Locally advanced or metastatic pancreatic adenocarcinoma;
3. Failure of standard treatment, >28 days after the last chemotherapy;
4. Patients not suitable for or having given up standard treatment;
5. At least one lesion measurable according to RECIST V 1.0 criteria;
6. ECOG score: 0～1;

7. Expected survival: ≥3 months;

   Haematological, biochemical and organ functions:

8. Hematological indices:

   • Absolute neutrophil count: ≥1.5×109/L;
   • Platelet count: ≥80×109/L;
   • Hemoglobin: ≥9.0 g/dL.
9. Total bilirubin: ≤1.5 x ULN, albumin: ≥3.0g/dL;
10. Patients without liver metastasis: ALT (SGPT) & AST (SGOT) ≤3.0 x ULN Patients with liver metastasis: ALT (SGPT) & AST (SGOT)≤5.0 x ULN;

11. Renal functions: serum creatinine ≤ 1.5xULN, Ccr ≥ 60ml/min (Cockcroft-Gault);

    General criteria for inclusion:

12. Age: 18～70;
13. Letter of Consent signed by the patient or his/her legal representative:
14. Women of childbearing age must have a urine pregnancy test within 7 days before starting treatment, only negative results shall be included in the group. Male and female patients of childbearing age have agreed to use a reliable method of contraception before and during participating the study as well as 90 days (at least) after withdrawal.

Exclusion Criteria:

Disease-related criteria for exclusion:

1. Patients of pancreatic tumor but not adenocarcinoma;
2. Having received radiotherapy for his/her target lesions prior to this study, with no progress;
3. Known presence of brain metastases or leptomeningeal metastases;
4. With Vater's ampulla cancer or bile duct cancer;
5. Partial or complete intestinal obstruction;

6. History of other malignancies in past five years, except for:

   • A consecutive 5-year disease-free survival from single surgery of other malignancies;
   • Cured basal cell carcinoma and cured cervical carcinoma in situ.

   General criteria for exclusion:

7. Pregnant or breast-feeding women;
8. Any unstable systemic disease, including: active infection; hypertension uncontrollable by medication (≥160/100mmHg); unstable angina, or angina with the onset from within the last three months; congestive heart failure (≥level II according to New York Heart Association [NYHA], see Annex 4); myocardial infarction occurred within 1 year before the enrollment; severe arrhythmias requiring medical treatment; and mental disorders, etc.;
9. Presence of active hepatitis B (history of hepatitis B infection, whether with or without medication, HBV DNA≥104 copy number or ≥2000u/ml) or HCV-Ab positive; known HIV-positive patients (no clinical signs or symptoms suggesting exemption of HIV test for HIV-infected individuals);

10. Having received any of the following treatment within specific time period before inclusion:

    • Having had a major surgery within 4 weeks before inclusion;
    • Having received expanded scope of radiotherapy within 4 weeks, or having received limited scope of radiotherapy within 2 weeks before inclusion;
    • Having participated in any other therapeutic/interventive clinical trials within 4 weeks before inclusion, or taking part in an ongoing trial.
11. With CTCAE toxicity at level II or above (excluding hair loss or skin pigmentation), uncured and caused by any previous treatment;
12. Not fitting in the study, as conceived by the researcher.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Group A:K-001 2700mg/d (1350mg BID); K-001 1350mg twice a day, to be taken with warm water on an empty stomach; 4 weeks' administration for each group.	Drug: K-001; In case of severe adverse reactions associated with the test drug, or if half of the participants show adverse reactions at Ⅲ level and above, the test should be terminated. The maximum dosage not causing the above-described situation shall be considered as the maximum tolerated dose or the biologically effective dose. After the test, continuous medication shall be given upon request from patients.; Other Names: Peptidoglycan Complex of Spirulina
Experimental: Group B: K-001 3240mg/d (1620mg BID); K-001 1620mg twice a day, to be taken with warm water on an empty stomach; 4 weeks' administration for each group.	Drug: K-001; In case of severe adverse reactions associated with the test drug, or if half of the participants show adverse reactions at Ⅲ level and above, the test should be terminated. The maximum dosage not causing the above-described situation shall be considered as the maximum tolerated dose or the biologically effective dose. After the test, continuous medication shall be given upon request from patients.; Other Names: Peptidoglycan Complex of Spirulina
Experimental: Group C: K-001 3780mg/d (1890mg BID); K-001 1890mg twice a day, to be taken with warm water on an empty stomach; 4 weeks' administration for each group.	Drug: K-001; In case of severe adverse reactions associated with the test drug, or if half of the participants show adverse reactions at Ⅲ level and above, the test should be terminated. The maximum dosage not causing the above-described situation shall be considered as the maximum tolerated dose or the biologically effective dose. After the test, continuous medication shall be given upon request from patients.; Other Names: Peptidoglycan Complex of Spirulina
Experimental: Group D: K-001 4320mg/d (2160mg BID); K-001 2160mg twice a day, to be taken with warm water on an empty stomach; 4 weeks' administration for each group.	Drug: K-001; In case of severe adverse reactions associated with the test drug, or if half of the participants show adverse reactions at Ⅲ level and above, the test should be terminated. The maximum dosage not causing the above-described situation shall be considered as the maximum tolerated dose or the biologically effective dose. After the test, continuous medication shall be given upon request from patients.; Other Names: Peptidoglycan Complex of Spirulina

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The maximum-tolerated dose (MTD) of K-001	The maximum-tolerated dose (MTD) of K-001 will be defined as the maximum dose level at which no more than one patient out of three experiences a dose-limiting toxicity (DLT) using Common Terminology Criteria for Adverse Events (CTCAE) criteria, version 4.0. If none of the patient experiences DLT, the maximum dose in the trial (4320mg/d) will be defined as MTD and the biologically effective dose.	day 29

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change of life quality assessed using EORTC QLQ-C30 V 3.0	EORTC QLQ-C30 V 3.0	within 7 days before taking drugs and day 8, day 15, day 22 and day 29
Change from Baseline of the Treg cell count	Laboratory tests: blood immunity test of FOXP3+CD4+Treg cell count	within 14 days before taking drugs, day 15 and day 29
Evaluation of suffered pains assessed using Numerical Rating Scale (NRS)	Numerical Rating Scale (NRS)	within 7 days before taking drugs and day 8, day 15, day 22 and day 29
Change from Baseline of the C-reactive protein (CRP)	Evaluation the level of CRP with laboratory tests of blood.	within 14 days before taking drugs, day 15 and day 29
Clinical efficacy of K-001 assessed by disease control rate (DCR) according to RECIST V 1.0 criteria	Evaluate patients with imaging, including CT/MRI of the chest, abdomen and pelvic, and get disease control rate (DCR) according to RECIST V 1.0 criteria.	day 29

Collaborators and Investigators

• Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
• Investigators: Study Director: Xingpeng Wang, MD, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Publications and helpful links

General Publications

• Cui J, Yang H, Liu J, Chen D, Hu J, Zhang H, Wang Y, Han T, Mao T, Jiao F, Biskup E, Pan Y, Liu M, Wang L. A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma. BMC Cancer. 2021 Jun 7;21(1):672. doi: 10.1186/s12885-021-08375-6.

Study record dates

Study Major Dates

• Study Start: January 1, 2016
• Primary Completion (Actual): December 1, 2016
• Study Completion (Actual): December 1, 2016

Study Registration Dates

• First Submitted: February 13, 2016
• First Submitted That Met QC Criteria: March 22, 2016
• First Posted (Estimate): March 28, 2016

Study Record Updates

• Last Update Posted (Estimate): January 6, 2017
• Last Update Submitted That Met QC Criteria: January 5, 2017
• Last Verified: January 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms; Neoplasms by Site; Endocrine System Diseases; Digestive System Neoplasms; Endocrine Gland Neoplasms; Pancreatic Diseases; Pancreatic Neoplasms
• Other Study ID Numbers: CPOG001_01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO